The funding, provided by investors including Qbic, will allow VUB and VIB spinout Confo Therapeutics to accelerate its drug discovery efforts and move towards clinical trials.

Confo Therapeutics, a Belgium-based drug discovery spinout of Vrije Universiteit Brussel (VUB) and research institute Vlaams Instituut voor Biotechnologie (VIB), has closed a €30m ($33.4m) series A round with investors including VIB.
Venture firms BioGeneration Ventures (BGV) and Wellington Partners Venture Capital co-led the round, with contributions from multi-university venture firm Qbic, whose remit includes VUB, as well as V-Bio Ventures, a venture fund allied to VIB.
The other participants were Michigan Investment in New Technology Startups (Mints),…